Patents by Inventor So-Young Eun

So-Young Eun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF
    Publication number: 20250388582
    Abstract: The present invention provides a novel compound represented by Chemical Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof. With an excellent inhibitory activity against PIKfyve, the novel compound of the present invention is useful as a therapeutic agent for PIKfyve activity-related cancer disease, inflammatory disease, or lysosomal storage disease.
    Type: Application
    Filed: July 12, 2023
    Publication date: December 25, 2025
    Inventors: Sunyoung Park, Hyojung Song, Kyusic Jang, Min Whan Chang, Minkyung Kim, Il Ji Jeong, Jongha Lim, Jisu Yoo, Woojin Jeon, Yoonsung Song, Hong Chul Yoon, Joon Tae Park, Jung Woo Lee, Kyung Mi An, Dongsik Park, Dasol Kim, Weonbin Im, So-Young Eun, Byong-Keol Min, Hong Jae Lee, Eunjung Kim, Eok Park
  • PHARMACEUTICALLY ACTIVE COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING PENDRIN
    Publication number: 20250340537
    Abstract: The present invention relates to a novel compound as pendrin corrector represented by the following Chemical formula 1 and a composition for preventing or treating pendred syndrome and the related disease thereof comprising the same as an active ingredient:
    Type: Application
    Filed: December 29, 2023
    Publication date: November 6, 2025
    Inventors: Jae Young CHOI, Gyoon Hee HAN, Min Goo LEE, Wan NAMKUNG, Jinsei JUNG, Sungwoo CHO, Shinhye NOH, Doona SONG, Dongsik PARK, Hong Jae LEE, Weonbin IM, So-Young EUN, Eok PARK, Mihwa SHIN
  • Anti-CEACAM1 antibody and use thereof
    Patent number: 11332528
    Abstract: The present invention provides anti-CEACAM1 antibodies with improved binding abilities specific to CEACAM1, and a use thereof. Anti-CEACAM1 antibodies according to the present invention exhibit superior binding abilities specific to CEACAM1, and also activate the anti-cancer immune functions of cytotoxic T cells and natural killer cells, and thus, each one of them can be effectively used as an anti-cancer agent and a composition for treating cancer.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: May 17, 2022
    Assignees: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, GREEN CROSS CORPORATION
    Inventors: So-Young Eun, Miyoung Oh, Hye-Young Park, Mijung Lee, Aerin Yoon, Hye In Yum, Hyemi Nam, Eunhee Lee, Jongwha Won
  • ANTI-CEACAM1 ANTIBODY AND USE THEREOF
    Publication number: 20200109196
    Abstract: The present invention provides anti-CEACAM1 antibodies with improved binding abilities specific to CEACAM1, and a use thereof. Anti-CEACAM1 antibodies according to the present invention exhibit superior binding abilities specific to CEACAM1, and also activate the anti-cancer immune functions of cytotoxic T cells and natural killer cells, and thus, each one of them can be effectively used as an anti-cancer agent and a composition for treating cancer.
    Type: Application
    Filed: March 23, 2018
    Publication date: April 9, 2020
    Applicants: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, GREEN CROSS CORPORATION
    Inventors: So-Young EUN, Miyoung OH, Hye-Young PARK, Mijung LEE, Aerin YOON, Hye In YUM, Hyemi NAM, Eunhee LEE, Jongwha WON
  • Methods and compositions for modulating T cell and/or B cell activation
    Patent number: 9296827
    Abstract: The present invention provides methods of reducing or enhancing T cell activation and/or B cell activation in a subject, comprising administering to a subject an effective amount of an inhibitor or enhancer, respectively, of Semaphorin 6D (Sema6D) activity on T cells and/or B cells.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: March 29, 2016
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Jenny P.-Y. Ting, Brian P. O'Connor, So-Young Eun, Zhengmao Ye
  • Methods and Compositions for Modulating T Cell and/or B Cell Activation
    Publication number: 20140050726
    Abstract: The present invention provides methods of reducing or enhancing T cell activation and/or B cell activation in a subject, comprising administering to a subject an effective amount of an inhibitor or enhancer, respectively, of Semaphorin 6D (Sema6D) activity on T cells and/or B cells.
    Type: Application
    Filed: July 2, 2013
    Publication date: February 20, 2014
    Applicant: University of North Carolina at Chapel Hill
    Inventors: Jenny P.-Y. Ting, Brian O'Connor, So-Young Eun, Zhengmao Ye
  • Methods and compositions for modulating T cell and/or B cell activation
    Patent number: 8501677
    Abstract: The present invention provides methods of reducing or enhancing T cell activation and/or B cell activation in a subject, comprising administering to a subject an effective amount of an inhibitor or enhancer, respectively, of Semaphorin 6D (Sema6D) activity on T cells and/or B cells.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: August 6, 2013
    Assignee: University of North Carolina at Chapel Hill
    Inventors: Jenny P.-Y. Ting, Brian P. O'Connor, So-Young Eun, Zhengmao Ye
  • METHODS AND COMPOSITIONS FOR MODULATING T CELL AND/OR B CELL ACTIVATION
    Publication number: 20120201836
    Abstract: The present invention provides methods of reducing or enhancing T cell activation and/or B cell activation in a subject, comprising administering to a subject an effective amount of an inhibitor or enhancer, respectively, of Semaphorin 6D (Sema6D) activity on T cells and/or B cells.
    Type: Application
    Filed: October 28, 2011
    Publication date: August 9, 2012
    Inventors: Jenny P.-Y. Ting, Brian P. O'Connor, So-Young Eun, Zhengmao Ye
  • METHODS AND COMPOSITIONS FOR MODULATING T CELL AND/OR B CELL ACTIVATION
    Publication number: 20090324615
    Abstract: The present invention provides methods of reducing or enhancing T cell activation and/or B cell activation in a subject, comprising administering to a subject an effective amount of an inhibitor or enhancer, respectively, of Semaphorin 6D (Sema6D) activity on T cells and/or B cells.
    Type: Application
    Filed: March 23, 2007
    Publication date: December 31, 2009
    Inventors: Jenny P.-T. Ting, Brian P. O'Connor, So-Young Eun, Zhengmao Ye